Search Results - "Aliazis, Konstantinos"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases by Ibis, Betul, Aliazis, Konstantinos, Cao, Carol, Yenyuwadee, Sasitorn, Boussiotis, Vassiliki A

    Published in Frontiers in immunology (05-06-2023)
    “…During the past decade, there has been a revolution in cancer therapeutics by the emergence of antibody-based immunotherapies that modulate immune responses…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Emergency myelopoiesis in solid cancers by Aliazis, Konstantinos, Yenyuwadee, Sasitorn, Phikulsod, Ployploen, Boussiotis, Vassiliki A.

    Published in British journal of haematology (01-09-2024)
    “…Summary Cells of the innate and adaptive immune systems are the progeny of haematopoietic stem and progenitor cells (HSPCs). During steady‐state myelopoiesis,…”
    Get full text
    Journal Article
  4. 4

    Pparβ/δ Has an Indispensable Role in T Cell Function and Anti-Tumor Responses by Ibis, Betul, Christofides, Anthos, Aliazis, Konstantinos, Shah, Rushil, Pal, Rinku, Boussiotis, Vassiliki A

    Published in Blood (02-11-2023)
    “…The peroxisome proliferator-activated receptors (PPARs) are a group of transcriptional factor of the nuclear hormone receptor superfamily, which promote…”
    Get full text
    Journal Article
  5. 5

    PD-1 Expression By Dendritic Cells Is a Key Regulator of T-Cell Immunity in Cancer by Shah, Rushil, Aliazis, Konstantinos, Christofides, Anthos, Pham, Angelique A, Pal, Rinku, Boussiotis, Vassiliki A

    Published in Blood (02-11-2023)
    “…Programmed cell death 1 (PD-1) is an inhibitory receptor expressed on a variety of immune cells and a therapeutic target of checkpoint immunotherapy for cancer…”
    Get full text
    Journal Article
  6. 6

    Specific PD-1 Deletion on Regulatory T Cells Leads to Enhanced Anti-Tumor Responses by Aliazis, Konstantinos, Christofides, Anthos, Aksoylar, Halil-Ibrahim, Shah, Rushil, Pal, Rinku, Patsoukis, Nikolaos, Boussiotis, Vassiliki A

    Published in Blood (02-11-2023)
    “…Programmed cell death 1 (PD-1) is a T cell inhibitory receptor and the most extensively exploited therapeutic target of checkpoint immunotherapy in cancer…”
    Get full text
    Journal Article
  7. 7

    Immune cellular components and signaling pathways in the tumor microenvironment by Yenyuwadee, Sasitorn, Aliazis, Konstantinos, Wang, Qi, Christofides, Anthos, Shah, Rushil, Patsoukis, Nikolaos, Boussiotis, Vassiliki A.

    Published in Seminars in cancer biology (01-11-2022)
    “…During the past decade there has been a revolution in cancer therapeutics by the emergence of antibody-based and cell-based immunotherapies that modulate…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    A four-cell pathway orchestrated by Flt3-L-dependent cDCs controls anti-tumor responses by Aliazis, Konstantinos, Boussiotis, Vassiliki A

    Published in Cell reports. Medicine (16-01-2024)
    “…A study by Régnier et al. shows that Flt3-ligand (FL) levels program two distinct mechanisms of anti-tumor immunity. Low FL levels allow recruitment of T…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    In Vitro and Ex Vivo Models to Study T Cell Migration Through the Human Liver Parenchyma by Wiggins, Benjamin G, Aliazis, Konstantinos, Davies, Scott P, Hirschfield, Gideon, Lalor, Patricia F, Reynolds, Gary, Stamataki, Zania

    “…The liver is the largest internal organ and filters around 3 pints of blood per minute. This continuous flux of blood should not be confused with rapid egress…”
    Get more information
    Journal Article